{"filing":{"accession_number":"0001185185-26-003691","cik":"0001098009","ticker":null,"company_name":"America Great Health","form":"8-K","filing_date":"2026-08-24","report_date":"2026-08-18","primary_document":"aagh8k081926.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1098009/000118518526003691/aagh8k081926.htm"},"events":[{"id":29157,"run_id":26682,"accession_number":"0001185185-26-003691","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"America Great Health discloses results of a preliminary clinical observation study of ion-modified peptide products (AX-3 and PPY-3) conducted at a Chinese hospital from December 2024 through May 2026. The study involved ten subjects with various malignancies and one inflammatory condition, with observations of clinical symptoms, vital signs, and laboratory parameters. While the company explicitly cautions that this was a small, non-randomized, non-blinded, non-placebo-controlled observational study with significant limitations, and that results cannot establish safety or efficacy, the disclosure of clinical research results on the company's lead investigational products is material to investors evaluating the company's pipeline and development prospects. This is an operational/strategic disclosure of research progress rather than a financial event, governance matter, or legal issue.","company_name":"America Great Health","ticker":null,"filing_date":"2026-08-24","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":31336,"accession_number":"0001185185-26-003691","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"America Great Health discloses results of a preliminary clinical observation study of ion-modified peptide products (AX-3 and PPY-3) conducted at a Chinese hospital from December 2024 through May 2026. The study involved ten subjects with various malignancies and one inflammatory condition, with observations of clinical symptoms, vital signs, and laboratory parameters. While the company explicitly cautions that this was a small, non-randomized, non-blinded, non-placebo-controlled observational study with significant limitations, and that results cannot establish safety or efficacy, the disclosure of clinical research results on the company's lead investigational products is material to investors evaluating the company's pipeline and development prospects. This is an operational/strategic disclosure of research progress rather than a financial event, governance matter, or legal issue.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-24T20:08:56.982169+00:00","company_name":"America Great Health","ticker":null,"filing_date":"2026-08-24"}]}